The immunology and immunotherapy of breast cancer: an update.
about
Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactionsDevelopment of new immunotherapy treatments in different cancer typesDiscovery of the breast cancer gene BASE using a molecular approach to enrich for genes encoding membrane and secreted proteins.Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays.Sialyl-tn in cancer: (how) did we miss the target?Carbohydrate recognition by boronolectins, small molecules, and lectins.Identification of novel tumor antigens with patient-derived immune-selected antibodies.Cytolytic T-cell response against Epstein-Barr virus in lung cancer patients and healthy subjects.Development of automated quantification methodologies of immunohistochemical markers to determine patterns of immune response in breast cancer: a retrospective cohort study.An overview of the management of recurrent breast cancer.Pathology of the breast associated with HIV/AIDS.Breast Cancer in the Setting of HIVInhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo.Alternative mechanism by which IFN-gamma enhances tumor recognition: active release of heat shock protein 72.Natural and adaptive IgM antibodies in the recognition of tumor-associated antigens of breast cancer (Review).Effects of a Shuangling Fuzheng anticancer preparation on the proliferation of SGC-7901 cells and immune function in a cyclophosphamide-treated murine model.Dendritic cell immunotherapy for breast cancer.Breast cancer stem cells: implications for therapy of breast cancer.Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.The MUC1 SEA module is a self-cleaving domain.Interferons alpha and gamma induce p53-dependent and p53-independent apoptosis, respectively.Mullerian inhibiting substance promotes interferon gamma-induced gene expression and apoptosis in breast cancer cells.Mitochondria-dependent and -independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-gamma in human breast tumour cells.Awareness and current knowledge of breast cancer.Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer.An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer.Comparison of autogeneic and allogeneic natural killer cells immunotherapy on the clinical outcome of recurrent breast cancer.Thymosin alpha1 as a chemopreventive agent in lung and breast cancer.Cetuximab combined with natural killer cells therapy: an alternative to chemoradiotherapy for patients with advanced non-small cell lung cancer (NSCLC).Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escapeCarbohydrate Biomarkers
P2860
Q24542471-43923F9F-5417-42D2-9E7C-B7C94A0B5C68Q24795087-1E8CCE45-D580-438D-A2DA-9747DDED2A42Q28069976-042CB92B-63DE-49FD-8DAD-DFBDF2A576DBQ30882620-64B9CDE4-1A65-45E4-8D32-566C227DF668Q31048160-50D3B0A1-4289-4707-8B75-766BFE0FD3ECQ33649572-4E8B2306-3001-4B94-ABE4-D225D02CFAC6Q33691290-2DA58C03-477D-4A2E-8860-A7135311A163Q33707586-7DF6D7FA-81E3-4FBB-9802-98965AD93A5CQ34010871-4FFE2131-45F2-45CF-9A99-7137F595A731Q34024612-8E56F01B-F803-4180-BB3A-C007FC5BDA3AQ34223488-17F0D956-0BBA-4BF3-91AE-02E815C8FF3EQ34722680-CDD1EE0B-3509-4483-92F7-2CF514C6FB17Q35026128-F8A63D24-F914-4CDD-9627-C66804FFC443Q35060303-20A04F04-EAC2-4F82-A655-6B1091752286Q35568966-9A1080AD-841F-4F44-8DB8-3BC423C01281Q35934485-866F16BF-B964-4699-B80E-5EA0CFFE9082Q36178217-4A94A4C5-DCB0-4582-A98A-AAEBFE375B34Q36480998-6D9D7C0B-D978-4C7B-B809-8FA637817D42Q36955061-6FE2D57F-EAA2-4A01-B330-7272626AFB31Q38293525-2BEA2F4E-A4E2-4890-902C-16E578D91216Q40040718-6E3C0996-0FF1-4A52-B652-C7BAE7589D16Q40403573-C0F03CD7-D662-4FC1-AF6E-68699B823B26Q40484622-A72D6DDC-0B16-4D14-A4CF-0CB84AE0AED2Q40628176-53FCDCA9-1D54-4290-ACBF-BA33BB9C5BCFQ42099676-8549F32B-3130-4F12-85EC-DC02AD0C138CQ42176053-C78638E5-470A-4279-967D-A0F8B3DFD51EQ47105585-0613F9A5-586D-417E-B725-31CD6DB8105CQ47135740-55F9912D-E6ED-437F-AD69-9DF2C4161CB8Q50145104-70E77FF4-36B3-49C1-BF44-BD9638415F46Q51750277-24B8716A-4527-4DBD-9EA9-2E224D36306EQ55005404-6DC50112-969C-47FC-BC00-D978712ED6ABQ57272360-171838D3-9BE5-4ECC-90E4-DF37C8D5E793Q57696972-E180A53A-0343-4B4E-82E6-D80BA15192C3
P2860
The immunology and immunotherapy of breast cancer: an update.
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The immunology and immunotherapy of breast cancer: an update.
@ast
The immunology and immunotherapy of breast cancer: an update.
@en
type
label
The immunology and immunotherapy of breast cancer: an update.
@ast
The immunology and immunotherapy of breast cancer: an update.
@en
prefLabel
The immunology and immunotherapy of breast cancer: an update.
@ast
The immunology and immunotherapy of breast cancer: an update.
@en
P1476
The immunology and immunotherapy of breast cancer: an update.
@en
P2093
P304
P356
10.1016/S0192-0561(98)00077-0
P577
1999-02-01T00:00:00Z